Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.

Coe MA, Jufer Phipps RA, Cone EJ, Walsh SL.

J Anal Toxicol. 2018 Jun 1;42(5):285-292. doi: 10.1093/jat/bky007.

PMID:
29462364
2.

Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing.

Altomare C, Kinzler ER, Buchhalter AR, Cone EJ, Costantino A.

J Opioid Manag. 2017 Nov/Dec;13(6):441-448. doi: 10.5055/jom.2017.0420. Review.

PMID:
29308590
3.

Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.

Schlienz NJ, Cone EJ, Herrmann ES, Lembeck NA, Mitchell JM, Bigelow GE, Flegel R, LoDico CP, Hayes ED, Vandrey R.

J Anal Toxicol. 2018 May 1;42(4):232-247. doi: 10.1093/jat/bkx102.

PMID:
29300962
4.

The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM.

Am J Drug Alcohol Abuse. 2017 May;43(3):291-298. doi: 10.1080/00952990.2016.1278006. Epub 2017 Feb 13.

PMID:
28448223
5.

Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.

Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ.

J Anal Toxicol. 2017 Mar 1;41(2):83-99. doi: 10.1093/jat/bkx012.

6.

Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.

Webster LR, Markman J, Cone EJ, Niebler G.

Postgrad Med. 2017 Jan;129(1):102-110. doi: 10.1080/00325481.2017.1268902. Epub 2016 Dec 12. Review. Erratum in: Postgrad Med. 2017 May;129(4):491.

PMID:
27915497
7.

Striving for Consensus on Approaches to Category 1 Testing of Abuse-Deterrent Formulations of Opioids: Discussions from the First Category 1 Focus Group Meeting.

Cone EJ, Sokolowska M, Lindhardt K.

Pain Pract. 2016 Sep;16(7):809-13. doi: 10.1111/papr.12488. No abstract available.

PMID:
27600925
8.

Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.

DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R, Cone EJ.

J Anal Toxicol. 2016 Oct;40(8):566-574. Epub 2016 Jul 11.

PMID:
27405370
9.

Prescription Opioids. VI. Metabolism and Excretion of Hydromorphone in Urine Following Controlled Single-Dose Administration.

DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R, Cone EJ.

J Anal Toxicol. 2016 Oct;40(8):575-582. Epub 2016 Jul 11.

PMID:
27405368
10.

Establishing "abuse-deterrence equivalence" for generic abuse-deterrent opioid formulations: A proposed development framework.

Setnik B, Cone EJ.

J Opioid Manag. 2016 May-Jun;12(2):96-100. doi: 10.5055/jom.2016.0320.

PMID:
27194193
11.

Metabolism and Disposition of Prescription Opioids: A Review.

DePriest AZ, Puet BL, Holt AC, Roberts A, Cone EJ.

Forensic Sci Rev. 2015 Jul;27(2):115-45. Review.

PMID:
26227254
12.

Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.

Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, Vandrey R.

J Anal Toxicol. 2015 Sep;39(7):497-509. doi: 10.1093/jat/bkv070. Epub 2015 Jul 2.

13.

Prescription Opioids. IV: Disposition of Hydrocodone in Oral Fluid and Blood Following Single-Dose Administration.

Cone EJ, DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R.

J Anal Toxicol. 2015 Sep;39(7):510-8. doi: 10.1093/jat/bkv050. Epub 2015 May 10.

PMID:
25962610
14.

Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects.

Herrmann ES, Cone EJ, Mitchell JM, Bigelow GE, LoDico C, Flegel R, Vandrey R.

Drug Alcohol Depend. 2015 Jun 1;151:194-202. doi: 10.1016/j.drugalcdep.2015.03.019. Epub 2015 Apr 6.

15.

Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.

Cone EJ, DePriest AZ, Heltsley R, Black DL, Mitchell JM, LoDico C, Flegel R.

J Anal Toxicol. 2015 Apr;39(3):192-202. doi: 10.1093/jat/bku176. Epub 2015 Jan 13.

PMID:
25589778
16.

Risks and responsibilities in prescribing opioids for chronic noncancer pain, part 2: best practices.

Cone EJ, DePriest AZ, Gordon A, Passik SD.

Postgrad Med. 2014 Nov;126(7):129-38. doi: 10.3810/pgm.2014.11.2841.

PMID:
25387221
17.

Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results.

Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, Vandrey R.

J Anal Toxicol. 2015 Jan-Feb;39(1):1-12. doi: 10.1093/jat/bku116. Epub 2014 Oct 17.

18.

Prescribing opioids for chronic noncancer pain in primary care: risk assessment.

Gordon A, Cone EJ, DePriest AZ, Axford-Gatley RA, Passik SD.

Postgrad Med. 2014 Sep;126(5):159-66. doi: 10.3810/pgm.2014.09.2810. Review.

PMID:
25295660
19.

Determining zolpidem compliance: urinary metabolite detection and prevalence in chronic pain patients.

Schwope DM, DePriest A, Black DL, Caplan YH, Cone EJ, Heltsley R.

J Anal Toxicol. 2014 Oct;38(8):513-8. doi: 10.1093/jat/bku068.

PMID:
25217539
20.

Prevalence of heroin markers in urine for pain management patients.

Knight J, Puet BL, DePriest A, Heltsley R, Hild C, Black DL, Robert T, Caplan YH, Cone EJ.

Forensic Sci Int. 2014 Oct;243:79-83. doi: 10.1016/j.forsciint.2014.04.037. Epub 2014 May 9.

PMID:
24858136
21.

Prescription opioids. II. Metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration.

Cone EJ, Heltsley R, Black DL, Mitchell JM, Lodico CP, Flegel RR.

J Anal Toxicol. 2013 Oct;37(8):486-94. doi: 10.1093/jat/bkt066. Epub 2013 Aug 14.

PMID:
23946451
22.

Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration.

Cone EJ, Heltsley R, Black DL, Mitchell JM, Lodico CP, Flegel RR.

J Anal Toxicol. 2013 Jun;37(5):255-64. doi: 10.1093/jat/bkt031. Epub 2013 Apr 21.

PMID:
23609023
23.

An iterative model for in vitro laboratory assessment of tamper deterrent formulations.

Cone EJ, Giordano J, Weingarten B.

Drug Alcohol Depend. 2013 Jul 1;131(1-2):100-5. doi: 10.1016/j.drugalcdep.2012.12.006. Epub 2013 Jan 17.

PMID:
23332441
24.

Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

Huestis MA, Cone EJ, Pirnay SO, Umbricht A, Preston KL.

Drug Alcohol Depend. 2013 Aug 1;131(3):258-62. doi: 10.1016/j.drugalcdep.2012.11.014. Epub 2012 Dec 14.

25.

Urine drug testing of chronic pain patients. V. Prevalence of propoxyphene following its withdrawal from the United States market.

Puet B, DePriest A, Knight J, Heltsley R, Black DL, Caplan YH, Cone EJ.

J Anal Toxicol. 2013 Jan-Feb;37(1):1-4. doi: 10.1093/jat/bks083. Epub 2012 Nov 5. Review.

PMID:
23129731
26.

Incorporation of methamphetamine and amphetamine in human hair following controlled oral methamphetamine administration.

Polettini A, Cone EJ, Gorelick DA, Huestis MA.

Anal Chim Acta. 2012 May 13;726:35-43. doi: 10.1016/j.aca.2012.01.042. Epub 2012 Jan 31.

27.

Is THC-COOH a useful determinant for passive inhalation in oral fluid THC testing?

Walsh JM, Cone EJ, Crouch DJ, Caplan YH.

J Anal Toxicol. 2012 May;36(4):291. doi: 10.1093/jat/bks034. No abstract available.

PMID:
22511704
28.

Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens.

Heltsley R, Depriest A, Black DL, Crouch DJ, Robert T, Marshall L, Meadors VM, Caplan YH, Cone EJ.

J Anal Toxicol. 2012 Mar;36(2):75-80. doi: 10.1093/jat/bkr019.

PMID:
22337775
29.

Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs.

Heltsley R, DePriest A, Black DL, Robert T, Marshall L, Meadors VM, Caplan YH, Cone EJ.

J Anal Toxicol. 2011 Oct;35(8):529-40.

PMID:
22004671
30.

Urine drug testing of chronic pain patients. IV. prevalence of gabapentin and pregabalin.

Heltsley R, Depriest A, Black DL, Robert T, Caplan YH, Cone EJ.

J Anal Toxicol. 2011 Jul;35(6):357-9.

PMID:
21740692
31.

Re: Pergolizzi et al., 2010: the role of urine drug testing for patients on opioid therapy.

Cone EJ, Caplan YH.

Pain Pract. 2011 May-Jun;11(3):309; author reply 310. No abstract available.

PMID:
21702095
32.

Oral fluid results compared to self reports of recent cocaine and heroin use by methadone maintenance patients.

Cone EJ.

Forensic Sci Int. 2012 Feb 10;215(1-3):88-91. doi: 10.1016/j.forsciint.2011.01.046. Epub 2011 Mar 4.

PMID:
21377302
33.

Barbiturate detection in oral fluid, plasma, and urine.

Fritch D, Blum K, Nonnemacher S, Kardos K, Buchhalter AR, Cone EJ.

Ther Drug Monit. 2011 Feb;33(1):72-9. doi: 10.1097/FTD.0b013e3182018151.

PMID:
21099741
34.

Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration.

Scheidweiler KB, Spargo EA, Kelly TL, Cone EJ, Barnes AJ, Huestis MA.

Ther Drug Monit. 2010 Oct;32(5):628-37. doi: 10.1097/FTD.0b013e3181f2b729.

35.
36.

Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites.

Heltsley R, Zichterman A, Black DL, Cawthon B, Robert T, Moser F, Caplan YH, Cone EJ.

J Anal Toxicol. 2010 Jan-Feb;34(1):32-8.

PMID:
20109300
37.

Urine drug testing of chronic pain patients. III. Normetabolites as biomarkers of synthetic opioid use.

Depriest A, Heltsley R, Black DL, Cawthon B, Robert T, Moser F, Caplan YH, Cone EJ.

J Anal Toxicol. 2010 Oct;34(8):444-9.

PMID:
21819788
38.

Identification and quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral fluid by liquid chromatography-tandem mass spectrometry.

Fritch D, Blum K, Nonnemacher S, Haggerty BJ, Sullivan MP, Cone EJ.

J Anal Toxicol. 2009 Nov-Dec;33(9):569-77.

PMID:
20040131
39.

Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives.

Cone EJ, Zichterman A, Heltsley R, Black DL, Cawthon B, Robert T, Moser F, Caplan YH.

Forensic Sci Int. 2010 May 20;198(1-3):58-61. doi: 10.1016/j.forsciint.2009.12.005. Epub 2009 Dec 29.

PMID:
20036472
40.

Urine toxicology testing in chronic pain management.

Cone EJ, Caplan YH.

Postgrad Med. 2009 Jul;121(4):91-102. doi: 10.3810/pgm.2009.07.2035. Review.

PMID:
19641275
41.

Multiple drug ingestion by ecstasy abusers in the United States.

Black DL, Cawthon B, Robert T, Moser F, Caplan YH, Cone EJ.

J Anal Toxicol. 2009 Apr;33(3):143-7.

PMID:
19371462
42.

Normalization of urinary drug concentrations with specific gravity and creatinine.

Cone EJ, Caplan YH, Moser F, Robert T, Shelby MK, Black DL.

J Anal Toxicol. 2009 Jan-Feb;33(1):1-7.

PMID:
19161663
43.

Caffeine content of brewed teas.

Chin JM, Merves ML, Goldberger BA, Sampson-Cone A, Cone EJ.

J Anal Toxicol. 2008 Oct;32(8):702-4.

PMID:
19007524
44.

Urine drug testing of chronic pain patients: licit and illicit drug patterns.

Cone EJ, Caplan YH, Black DL, Robert T, Moser F.

J Anal Toxicol. 2008 Oct;32(8):530-43.

PMID:
19007501
45.

Rapid absorption of nicotine from new nicotine gum formulations.

Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, Pinney JM, Chau T.

Pharmacol Biochem Behav. 2009 Jan;91(3):380-4. doi: 10.1016/j.pbb.2008.08.012. Epub 2008 Aug 16.

PMID:
18762208
46.

Time of heroin use.

Jenkins AJ, Cone EJ.

J Anal Toxicol. 2008 Jul-Aug;32(6):454-6. No abstract available.

PMID:
18652754
47.

Evidence that morphine is metabolized to hydromorphone but not to oxymorphone.

Cone EJ, Caplan YH, Moser F, Robert T, Black D.

J Anal Toxicol. 2008 May;32(4):319-23.

PMID:
18430301
48.

Cocaine and metabolites urinary excretion after controlled smoked administration.

Huestis MA, Darwin WD, Shimomura E, Lalani SA, Trinidad DV, Jenkins AJ, Cone EJ, Jacobs AJ, Smith ML, Paul BD.

J Anal Toxicol. 2007 Oct;31(8):462-8.

49.

Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid.

Cone EJ, Clarke J, Tsanaclis L.

J Anal Toxicol. 2007 Oct;31(8):424-33. Erratum in: J Anal Toxicol. 2008 Mar;32(2):199-200.

PMID:
17988455
50.

Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.

Barnes AJ, Smith ML, Kacinko SL, Schwilke EW, Cone EJ, Moolchan ET, Huestis MA.

Clin Chem. 2008 Jan;54(1):172-80. Epub 2007 Nov 2.

Supplemental Content

Support Center